1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 15th April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms, 2022, Mukherjee et al

Discussion in 'Long Covid research' started by Wyva, Sep 26, 2022.

Tags:
  1. Wyva

    Wyva Senior Member (Voting Rights)

    Messages:
    1,391
    Location:
    Budapest, Hungary
    Abstract

    Background Autoimmunity has been reported in patients with severe COVID-19. We investigated whether antinuclear/extractable-nuclear antibodies (ANAs) were present up to a year after infection, and if they were associated with the development of clinically relevant Post-Acute Sequalae of COVID-19 (PASC) symptoms.

    Methods A rapid assessment line immunoassay was used to measure circulating levels of ANA/ENAs in 106 convalescent COVID-19 patients with varying acute phase severities at 3, 6, and 12 months post-recovery. Patient-reported fatigue, cough, and dyspnea were recorded at each timepoint. Multivariable logistic regression model and receiver-operating curves (ROC) were used to test the association of autoantibodies with patient-reported outcomes and pro-inflammatory cytokines.

    Results Compared to age- and sex-matched healthy controls (n=22) and those who had other respiratory infections (n=34), patients with COVID-19 had higher detectable ANAs at 3 months post-recovery (p<0.001). The mean number of ANA autoreactivities per individual decreased from 3 to 12 months (3.99 to 1.55) with persistent positive titers associated with fatigue, dyspnea, and cough severity. Antibodies to U1-snRNP and anti-SS-B/La were both positively associated with persistent symptoms of fatigue (p<0.028, AUC=0.86) and dyspnea (p<0.003, AUC=0.81). Pro-inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and C-reactive protein predicted the elevated ANAs at 12 months. TNFα, D-dimer, and IL-1β had the strongest association with symptoms at 12 months. Regression analysis showed TNFα predicted fatigue (β=4.65, p=0.004) and general symptomaticity (β=2.40, p=0.03) at 12 months.

    Interpretation Persistently positive ANAs at 12 months post-COVID are associated with persisting symptoms and inflammation (TNFα) in a subset of COVID-19 survivors. This finding indicates the need for further investigation into the role of autoimmunity in PASC.

    Paywall: https://erj.ersjournals.com/content/early/2022/08/04/13993003.00970-2022
     
    Wyva, Sep 26, 2022
    #1
    Mij, ukxmrv, Ariel and 6 others like this.
  2. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,933
    Location:
    Aotearoa New Zealand
    Canadian study, unfortunately with a paywall.

    Link to an article about it
    https://www.cidrap.umn.edu/news-per...ifficulty-exercising-noted-1-year-after-covid

    That separation between (severe) Covid-19 survivors and healthy volunteers (at 6 months 80%, at 1 year 41% versus 'most healthy volunteers had no evidence of these antibodies') sounds interesting. As does the link between patients having the two named antibodies and fatigue.

    I would have thought there would be a study looking at antibodies to U1-snRNP in ME/CFS, although in a quick search I didn't find one.

    We have this, where it's suggested that the loss of U1 snRNP affects glycolysis.
    Loss of LUC7L2 and U1 snRNP subunits shifts energy metabolism from glycolysis to OXPHOS, 2021, Jourdain et al
     
    Last edited: Sep 26, 2022
    Hutan, Sep 26, 2022
    #2
    RedFox, bobbler, Sean and 4 others like this.

Share This Page